Endoscopic ultrasound-guided radiofrequency ablation for hepatocellular carcinoma in cirrhosis: a case report test for efficacy and future perspectives
Background The percutaneous approach allows for effective and safe treatment of liver lesions. But in case of subcapsular or left segments location, this approach seems to be less effective or unsafe. Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is a new technique used to treat pancreatic and neuroendocrine tumors in patients unfit for surgery.
Methods Hereby, we describe the case of a 70-year-old patient with cirrhosis with a large subcapsular hepatocellular carcinoma (HCC) in II-III-IVb segments, in which surgery or percutaneous therapies were not feasible, treated with EUS-RFA. The HCC was treated using an EUS-RFA (EUSRA) system, which consists of a 19G water-cooled monopolar RFA needle and a dedicated generator system.
Results After a multidisciplinary discussion, the lesion was ablated in two different sessions, which resulted in destruction of about 70 % of neoplastic tissue. A second step surgery was required but initially refused by the patient.
Conclusions EUS-RFA could be an effective way to treat left hepatic lesions not manageable with conventional percutaneous methods. This case report does not highlight concerns about safety of this approach and this observation needs to be validated in a larger cohort of patients with cirrhosis.
Received: 27 April 2020
Accepted: 15 July 2020
22 October 2020 (online)
© 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 Jemal A, Bray F, Center MM. et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90
- 2 Galle Peter R. et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatology 2018; 69: 182-236
- 3 McDermott S, Gervais DA. Radiofrequency ablation of liver tumors. Semin Intervent Radiol 2013; 30: 49-55
- 4 Peng ZW, Lin XJ, Zhang YJ. et al. Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study. Radiology 2012; 262: 1022-1033
- 5 Pai M, Habib N, Senturk H. et al. Endoscopic ultrasound guided radiofrequency ablation, for pancreatic cystic neoplasms and neuroendocrine tumors. World J Gastrointest Surg 2015; 7: 52-9
- 6 Attili F, Boskiski I, Bove V. et al. EUS-guided radiofrequency ablation of a hepatocellular carcinoma of the liver. VideoGIE 2018; 3: 149-150
- 7 Berzigotti A, Seijio S, Reverter E. et al. Assessing portal hypertension in liver diseases. Exp Rev Gastroenterol Hepatol 2013; 2: 141-155
- 8 Seror O, Haddar D, N'Kontchou G. et al. Radiofrequency ablation for the treatment of liver tumors. JVIR 2005; 12: 981-990
- 9 Scopelliti F, Pea A, Conigliaro R. et al. Technique, safety, and feasibility of EUS-guided radiofrequency ablation in unresectable pancreatic cancer. Surg Endosc 2018; 3: 4022-4028
- 10 Vilana R, Bianchi L, Varela M. et al. Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early HCC?. Eur Radiol 2006; 16: 2454-2462